Design / Schedule

Design / Schedule

Research Design

Research type

JIPS Registry is a multi-site, non-interventional, prospective observation study.

Target case

Newly diagnosed IIPs within 6 months before registration.

Target case number

600-800 patients will be registered for 16 months at approximately 70-80 facilities in Japan.

Sample size

JIPS Registry is an observational study, and no formal sample size was calculated. Descriptive statistical methods will be mainly chosen to analyze the results.
The sample size of INSIGHT-IPF was at least 500 patients and IPF-PRO was 300 patients. Therefore, at least 200 IPF patients who fulfill the diagnostic criteria for IPF will be enrolled in the JIPS registry as it is an adequate number to obtain meaningful outcomes and allows for comparison with other cohorts. Based on the historical volume of two hospitals, in the Tosei General Hospital and Kanagawa Cardiovascular Respiratory Center, which have at least 100 IIPs patients per year, IPF patients comprise approximately 30-40% of IIPs at each facility, providing an expected IPF population of at least 200 patients.

Research period

Registration period:December 2016-March 2018
Tracking period:3 years from the end of the last registration (The maximum observation period will be 52 months.)


Inclusion criteria

Patients need to meet all the following inclusion criteria:

  1. Patients aged between 20 and 84 years
  2. Patients with IPF and other IIPs diagnosis within 6 months before registration at each facility
  3. Patients from whom written informed consent has been obtained regarding participation in this study and follow-up observation

Exclusion criteria

Patients with any of the following criteria are excluded from this study:

  1. Patients for whom the tests (such as the lung function test) conducted in this study could not be performed
  2. Patients who underwent pulmonary resection
  3. Patients undergoing dialysis
  4. Patients with uncured cancer

Registry schedule

This research will consist of a baseline and a follow-up visit at approximately 6-month intervals (6, 12, 18, 24, 30, 36, 42, 48 months) throughout the observational period.

Registry Schedule

Figure-Registry Schedule

  1. Data on current practice patterns for IIPs diagnosis

    Describe the frequency of surgical lung biopsy, bronchoalveolar lavage, lung function tests, 6-minuite walk test and chest CT.

  2. Prevalence of each categorized IIPs

    Investigate the prevalence of each categorized IIPs by using the recent and future guidelines.

  3. Natural history of each categorized IIPs

    Describe the natural history of each categorized IIPs, CT findings, FVC changes, medications, and causes of death.

  • STEP 1

    Newly diagnosed idiopathic interstitial pneumonias

  • STEP 2

    To verify eligibility in the office

  • STEP 3


  • STEP 4

    To put the information into database
    (Registry sheets, HRCT and pathological data)

  • STEP 5

    MDD conducting within 3 months after registration by the central committee
    (IPF, NSIP, UnclassifiableIIPs, COP, et al.)

  • STEP 6

    Diagnostic central review for unscheduled hospitalization with acute exacerbation.

  • STEP 7

    Stable phase

  • STEP 8

    Follow up every 6 months
    (Blood test, lung function test, et al.)

  • STEP 9

    Follow up every 12 months
    (HRCT, 6WMT, SGRQ, et al.)

  • STEP 10

    To continue the investigations for 3 years after registry

  • STEP 11

    Data analysis, final MDD conducting by the central committee
    (Working diagnosis)

Survey Schedule

◎:Mandatory survey item, ○:Survey item

Survey items At registration Every 6 months Every 12 months
Diagnosis and diagnostic change
Data of pathological findings
Prognostic information
Patient background
Physical findings
Clinical exams Serum biomarkers
Blood tests
Arterial blood gas analysis
Lung function test
6-min walk test
Cardiac ultrasound
Image inspections Chest X-ray
Chest CT
Presence or absence of CPFE
Data of bronchoalveolar lavage
Confirmation of home oxygen therapy
Confirmation of respiratory rehab
Clinical events
(lung cancer, pneumothorax,
pneumonia, etc.)
Patient-reported outcome(SGRQ, CAT)
Prediction of disease behavior by physician
Treatment information
Adverse events